Processa Pharmaceuticals Inc., a clinical-stage pharmaceutical company, has announced updates on its product pipeline and forthcoming clinical studies. The company is actively enrolling patients in its NGC-Cap Phase 2 clinical trial for metastatic breast cancer, with initial data anticipated to be shared in the second half of 2025. Additionally, Processa is designing a new adaptive pivotal Phase III study for PCS499, following preliminary positive results in kidney disease and the FDA's allowance of surrogate endpoints in rare kidney diseases. The company is also establishing a dedicated subsidiary to enhance strategic flexibility in capital raising and partnership exploration for PCS499. Results for these studies have not yet been presented and are expected in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.